170570-80-6

Basic information

• Product Name: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-fluorophenyl)-, methyl ester
• CAS NO: 170570-80-6
• Molecular Formula: C17H14FN3O4S
• Molecular Weight: 375.38
• Mol File: 170570-80-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-fluorophenyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-fluorophenyl)-, methyl ester(170570-80-6)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-fluorophenyl)-, methyl ester(170570-80-6)

Safety Data

• Hazardous Substances Data: 170570-80-6(Hazardous Substances Data)

Upstream product

• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 
• 39757-34-1 methyl 4-(4-fluorophenyl)-2,4-diketobutyrate 
• 553-90-2 Dimethyl oxalate 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 4392-54-5 4-aminosulfonylphenylhydrazine 
• 124-41-4 sodium methylate 
• 156276-23-2 methyl (p-fluorobenzoyl)formate 
• 41167-60-6 4-(4-fluorophenyl)-4-oxo-2-hydroxy-2-butenoic acid methyl ester 

Downstream Products

• 170571-29-6 1-[4-(aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 
• 170570-81-7 5-(4-fluorophenyl)-1-(4-sulfamoylphenyl)-1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates

As an essential enzyme with a variety of physiological functions, Cyclooxygenase-2 (COX-2) is also closely related to carcinoma due to the observed overexpression. In this work, a novel series of sulfonamide-containing aminophosphonate derivatives (A1-A25

Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents

In this paper, 41 hybrid compounds containing diaryl-1,5-diazole and morpholine structures acting as dual COX-2/5-LOX inhibitors have been designed, synthesized and biologically evaluated. Most of them showed potent antiproliferative activities and COX-2/5-LOX inhibitory in vitro. Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43–10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs. celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM). Meanwhile, the molecular modeling study was performed to position compound A33 into COX-2 and 5-LOX active sites to determine the probable binding models. Mechanistic studies demonstrated that compound A33 could block cell cycle in G2 phase and subsequently induced apoptosis of F10 cells. Furthermore, compound A33 could significantly inhibit tumor growth in F10-xenograft mouse model, and pharmacokinetic study of compound A33 indicated that it showed better stability in vivo. In general, compound A33 could be a promising candidate for cancer therapy.

Design, synthesis and evaluation of benzenesulfonamide-substituted 1,5-diarylpyrazoles containing phenylacetohydrazide derivatives as COX-1/COX-2 agents against solid tumors

Novel benzenesulfonamide-substituted 1,5-diarylpyrazoles containing phenylacetohydrazide derivatives have been designed, synthesized and evaluated for their biological activities as selective COX-2 inhibitors with anticancer potential. In vitro the bioass